Sugi Predict

Sugi Predict / Compounds / SCHEMBL179481

SCHEMBL179481

SCHEMBL179481

Cn1cc(C(C)(C)C)cn1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5B Q9UGL1 1/20 0.33
▸ PLAU P00749 1/20 0.33
▸ ELANE P08246 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ HTT P42858 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ BRD4 O60885 1/20 0.31
▸ SLC22A12 Q96S37 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ EPHX2 P34913 1/20 0.30
▸ ALOX5AP P20292 1/20 0.30
▸ AURKA O14965 1/20 0.30
▸ TTK P33981 1/20 0.30
▸ AURKB Q96GD4 1/20 0.30
▸ INCENP Q9NQS7 1/20 0.30
▸ ADRA2A P08913 1/20 0.30
▸ ADRA2B P18089 1/20 0.30
▸ ADRA2C P18825 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16472327 0.84 PLAU (0.30) PLAUELANE
SCHEMBL28035651 0.83 ALDH1A1 (0.32) ALDH1A1HTTSMN1; SMN2L3MBTL1BRD4
SCHEMBL19841860 0.82 PIM1 (0.33) —
SCHEMBL19135627 0.81 ALDH1A1 (0.31) ALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL19815546 0.81 PIK3CD (0.33) ALDH1A1HTTSMN1; SMN2L3MBTL1ALOX5AP
SCHEMBL23154609 0.81 ALDH1A1 (0.34) ALDH1A1HTTSMN1; SMN2L3MBTL1SLC22A12
SCHEMBL26858663 0.81 KCNH2 (0.35) ALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL2611113 0.80 NPBWR1 (0.41) ALDH1A1HTTSMN1; SMN2L3MBTL1EPHX2
SCHEMBL12221287 0.78 PLAU (0.32) PLAUELANE
SCHEMBL19889761 0.78 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 949 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043613-B2 Inhibitors of SARM1 DISARM THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-11 — — US disclosed
US-20240216377-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION 2024-07-04 — — US disclosed
US-20240216377-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION 2024-07-04 — — US disclosed
US-12024500-B2 Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) 2024-07-02 — — US disclosed
US-20240209017-A1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-06-27 — — US disclosed
US-20240209000-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE LLC 2024-06-27 — — US disclosed
US-20240209000-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE LLC 2024-06-27 — — US disclosed
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2008-01-24 — — US disclosed
US-20080004273-A1 Inhibitors of protein tyrosine kinase activity METHYLGENE, INC. (CA) 2008-01-03 — — US disclosed
US-20080004273-A1 Inhibitors of protein tyrosine kinase activity METHYLGENE, INC. (CA) 2008-01-03 — — US disclosed
US-20070287705-A1 Crf Receptor Antagonists and Methods Relating Thereto NEUROCRINE BIOSCIENCES, INC. 2007-12-13 — — US disclosed
US-20070083044-A1 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORPORATION 2007-04-12 — — US disclosed
US-20070082900-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-04-12 — — US disclosed
US-20070082901-A1 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORPORATION 2007-04-12 — — US disclosed
US-20070082902-A1 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORPORATION 2007-04-12 — — US disclosed
US-20070072898-A1 Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof TEIJIN PHARMA LIMITED 2007-03-29 — — US disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12024500-B2 Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof DDT, CYP3A5, CYP4B1 KDM5B 298/4885PLAU 4195/4885ELANE 4720/4885
US-20070072898-A1 Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof MAPKAPK2, MAP4K2, MAPKAPK5 KDM5B 1394/4885PLAU 1621/4885ELANE 2327/4885
US-20240216377-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB KDM5B 1064/4885PLAU 4669/4885ELANE 3521/4885
US-20070287705-A1 Crf Receptor Antagonists and Methods Relating Thereto CRHR1, CRHR2, CRH KDM5B 4162/4885PLAU 980/4885ELANE 942/4885
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP KDM5B 3914/4885PLAU 3239/4885ELANE 1734/4885
US-20240209000-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PIK3CA, PIK3CG, PIK3CD KDM5B 4164/4885PLAU 1442/4885ELANE 1806/4885
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 KDM5B 4155/4885PLAU 769/4885ELANE 3793/4885
US-20070082901-A1 Pyrazolopyrimidines as protein kinase inhibitors CHEK1, CHEK2, BUB1 KDM5B 983/4885PLAU 3295/4885ELANE 4583/4885
US-20070082900-A1 Methods for inhibiting protein kinases PIM1, AURKC, PIM3 KDM5B 1065/4885PLAU 2955/4885ELANE 4832/4885
US-12043613-B2 Inhibitors of SARM1 SARM1, SMN1; SMN2, SARNP KDM5B 3969/4885PLAU 3518/4885ELANE 3751/4885
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 KDM5B 1903/4885PLAU 2285/4885ELANE 1898/4885
US-20240209017-A1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING STING1, CGAS, MAVS KDM5B 2268/4885PLAU 4535/4885ELANE 2123/4885
US-20070083044-A1 Pyrazolopyrimidines as protein kinase inhibitors CHEK1, CHEK2, BUB1 KDM5B 909/4885PLAU 3501/4885ELANE 4674/4885
US-20070082902-A1 Pyrazolopyrimidines as protein kinase inhibitors CHEK1, CHEK2, BUB1 KDM5B 983/4885PLAU 3295/4885ELANE 4583/4885
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase BACE1, BACE2, PSEN1 KDM5B 3601/4885PLAU 4170/4885ELANE 3210/4885
US-20080004273-A1 Inhibitors of protein tyrosine kinase activity HGF, ERBB2, MET KDM5B 1985/4885PLAU 959/4885ELANE 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.